Dr. McCurdy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Fl 12
Philadelphia, PA 19104Phone+1 215-385-2776Fax+1 215-615-3349
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Pennsylvania Health SystemResidency, Internal Medicine, 2009 - 2012
Georgetown University School of MedicineClass of 2009
Certifications & Licensure
PA State Medical License 2009 - 2024
MD State Medical License 2012 - 2019- American Board of Internal MedicineOncology
Awards, Honors, & Recognition
- Most Cited Articles for Grade 2 Acute GVHD and Higher Nucleated Dose Improves PFS after HLA-Haploidentical BMT with PTCy Biology of Blood and Marrow Transplantation, 2019
- Conquer Cancer Young Investigator Award American Society of Clinical Oncology, 2015
- American Society of Hematology, Abstract Achievement Award American Society of Hematology, 2014
- Join now to see all
Clinical Trials
- Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies Start of enrollment: 2018 Sep 21
- APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Start of enrollment: 2019 Jan 11
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) Start of enrollment: 2019 Jun 14
- Join now to see all
Publications & Presentations
PubMed
- 45 citationsReal-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.Andrew H Matthews, Alexander E Perl, Selina M Luger, Alison W Loren, Saar I Gill
Blood Advances. 2022-07-12 - 28 citationsHow I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.Joseph Rimando, Shannon R McCurdy, Leo Luznik
Blood. 2023-01-05 - 58 citationsNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Peter L Greenberg, Richard M Stone, Aref Al-Kali, John M Bennett, Uma Borate
Journal of the National Comprehensive Cancer Network. 2022-02-01
Abstracts/Posters
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractShannon R. McCurdy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Penn Medicine at the 2023 ASH MeetingDecember 7th, 2023- Tailoring Therapy in Older Adults with Hematologic MalignanciesMay 30th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
